Statins Persist as Preferred Drug Class for Dyslipidemia Therapeutics Through 2028

According to a recently released Fact.MR study, revenues from dyslipidemia therapeutics market surpassed US$ 36 billion in 2018. Low-density lipoproteins held approximately two-thirds of revenues from dyslipidemia therapeutics worldwide in 2018. As high LDL levels have been associated with increased risks of heart attacks, strokes, and other cardiovascular problems in humans, governments around the world are launching various campaigns to raise […]

Dyslipidemia Therapeutics Market Growth, Trends, Absolute Opportunity and Value Chain 2021-2031

A recently compiled Fact.MR report, titled “Dyslipidemia Therapeutics Market Forecast, Trend Analysis & Competition Tracking – Global Review 2018-2028” provides a comprehensive analysis of the dyslipidemia therapeutics market. The dyslipidemia therapeutics market report commences with an executive summary of the dyslipidemia therapeutics market which provides brief yet affluent information about the market along with exclusive recommendations by Fact.MR and a thorough analysis […]